0.4893  -0.016 (-3.13%)		07-26 16:00
Open: 0.5 High: 0.529 Volume: 50,864		Pre. Close: 0.5051 Low: 0.4873 Market Cap: 9(M)

Short term
Mid term
Targets	6-month :	0.66	1-year :	0.75
Resists	First :	0.56	Second :	0.65
Pivot price	0.5
Supports	First :	0.43	Second :	0.36
MAs	MA(5) :	0.49	MA(20) :	0.49
	MA(100) :	0.58	MA(250) :	0.7
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	23.6	D(3) :	26.8
RSI	RSI(14): 47.1
52-week	High :	3.39	Low :	0.31

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BGLC ] has closed above bottom band by 34.9%. Bollinger Bands are 61% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.53 - 0.53	0.53 - 0.54
Low:	0.48 - 0.48	0.48 - 0.49
Close:	0.48 - 0.49	0.49 - 0.49

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Thu, 18 Jul 2024
BioNexus Gene Lab Corp. (NASDAQ:BGLC) Sees Significant Growth in Short Interest - American Banking and Market News

Fri, 19 Apr 2024
BioNexus Gene Lab invests $250K for AI-based healthcare innovation in Malaysia - BSA bureau

Fri, 19 Apr 2024
Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today? - InvestorPlace

Thu, 18 Apr 2024
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in - GlobeNewswire

Thu, 15 Feb 2024
symbol__ Stock Quote Price and Forecast - CNN

Wed, 14 Feb 2024
Companies Like BioNexus Gene Lab (NASDAQ:BGLC) Can Afford To Invest In Growth - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	18 (M)
Shares Float	10 (M)
Held by Insiders	64.3 (%)
Held by Institutions	0.5 (%)
Shares Short	189 (K)
Shares Short P.Month	58 (K)

EPS	-0.19
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.52
Profit Margin	-27.3 %
Operating Margin	-3.4 %
Return on Assets (ttm)	-13.4 %
Return on Equity (ttm)	-33.5 %
Qtrly Rev. Growth	0.2 %
Gross Profit (p.s.)	0
Sales Per Share	0.55
EBITDA (p.s.)	-0.12
Qtrly Earnings Growth	0 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	1 (M)

PE Ratio	-2.58
PEG Ratio	0
Price to Book value	0.92
Price to Sales	0.88
Price to Cash Flow	-7.09

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.